



NEWS RELEASE

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

2025-02-26

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in March:

Leerink Global Healthcare Conference 2025

Date: Wednesday, March 12th , 2025

Location: Miami Beach, FL

Format: Fireside chat & 1x1 meetings

Time: 8:00 a.m. ET

Barclays 27th Annual Global Healthcare Conference

Date: Thursday, March 13th , 2025

Location: Miami Beach, FL

Format: Fireside chat & 1x1 meetings

Time: 8:00 a.m. ET

Live webcasts of the fireside chats and panel will be available by visiting the "Investors & Media" section of the Arcus Biosciences website at www.arcusbio.com. Replays will be available following the live event.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2α, CD73, A2a/A2b receptors, CD39 and AXL. For more information about Arcus Biosciences's clinical and preclinical programs, please visit www.arcusbio.com.

Investor Inquiries

Pia Eaves (Banerjee)

Head of Investor Relations & Strategy

(617) 459-2006

peaves@arcusbio.com

Media Inquiries

Holli Kolkey

VP of Corporate Communications

(650) 922-1269

hkolkey@arcusbio.com

Maryam Bassiri

AD, Corporate Communications

(510) 406-8520

mbassiri@arcusbio.com

Source: Arcus Biosciences